While both POSTN and CCL2 have been previously implicated in promoting GBM aggressiveness [35,37,38], this is the first study that demonstrates effective pharmacological inhibition of these cytokines in vivo, using a combination of EGFR and MTOR-targeted drugs. The gene discussed is MTOR; the disease is glioblastoma.